arXiv · 2209.13371
Considerations and recommendations from the ISMRM Diffusion Study Group for preclinical diffusion MRI: Part 2 -- Ex vivo imaging: added value and acquisition
Abstract
The value of preclinical diffusion MRI (dMRI) is substantial. While dMRI enables in vivo non-invasive characterization of tissue, ex vivo dMRI is increasingly used to probe tissue microstructure and brain connectivity. Ex vivo dMRI has several experimental advantages including higher signal-to-noise ratio and spatial resolution compared to in vivo studies, and enabling more advanced diffusion contrasts. Another major advantage of ex vivo dMRI is the direct comparison with histological data as a methodological validation. However, there are a number of considerations that must be made when performing ex vivo experiments. The steps from tissue preparation, image acquisition and processing, and interpretation of results are complex, with decisions that not only differ dramatically from in vivo imaging of small animals, but ultimately affect what questions can be answered using the data. This work represents "Part 2" of a 3-part series of recommendations and considerations for preclinical dMRI. We describe best practices for dMRI of ex vivo tissue, with a focus on the value that ex vivo imaging adds to the field of dMRI and considerations in ex vivo image acquisition. We give general considerations and foundational knowledge that must be considered when designing experiments. We describe differences in specimens and models and discuss why some may be more or less appropriate for different studies. We then give guidelines for ex vivo protocols, including tissue fixation, sample preparation, and MR scanning. In each section, we attempt to provide guidelines and recommendations, but also highlight areas for which no guidelines exist (and why), and where future work should lie. An overarching goal herein is to enhance the rigor and reproducibility of ex vivo dMRI acquisitions and analyses, and thereby advance biomedical knowledge.
Explore related subjects
Keep this discovery
Kurt G Schilling, Francesco Grussu, Andrada Ianus, Brian Hansen, Amy FD Howard, Rachel L C Barrett, Manisha Aggarwal, Stijn Michielse, Fatima Nasrallah, Warda Syeda, Nian Wang, Jelle Veraart, Alard Roebroeck, Andrew F Bagdasarian, Cornelius Eichner, Farshid Sepehrband, Jan Zimmermann, Lucas Soustelle, Christien Bowman, Benjamin C Tendler, Andreea Hertanu, Ben Jeurissen, Lucio Frydman, Yohan van de Looij, David Hike, Jeff F Dunn, Karla Miller, Bennett A Landman, Noam Shemesh, Adam Anderson, Emilie McKinnon, Shawna Farquharson, Flavio Dell' Acqua, Carlo Pierpaoli, Ivana Drobnjak, Alexander Leemans, Kevin D Harkins, Maxime Descoteaux, Duan Xu, Hao Huang, Mathieu D Santin, Samuel C. Grant, Andre Obenaus, Gene S Kim, Dan Wu, Denis Le Bihan, Stephen J Blackband, Luisa Ciobanu, Els Fieremans, Ruiliang Bai, Trygve Leergaard, Jiangyang Zhang, Tim B Dyrby, G Allan Johnson, Julien Cohen-Adad, Matthew D Budde, Ileana O Jelescu. 2022-09-27. Considerations and recommendations from the ISMRM Diffusion Study Group for preclinical diffusion MRI: Part 2 -- Ex vivo imaging: added value and acquisition. https://arxiv.org/abs/2209.13371
Cite the original work for its findings. Save a collection to share your selection of sources.